Skip to content

Author

E. Calvo

We have 4 of 61 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

LGR5-high colorectal cancer defines a Wnt-active stem-like state with multimodal therapeutic vulnerabilities

Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) marks a stem-like colorectal cancer population but is difficult to target directly because of its expression in normal intestinal stem cells. Here, we integrated transcriptomic, somatic mutation, and copy-number data from 396 colorectal tumors to define...

Lucía Paniagua-Herranz, A. Feito, Cristian Privat et al. · 0 citations
Open access Sep 2026

16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy

ABBV-CLS-484 is tolerable, with preliminary evidence of clinical activity in dose escalation, and additional strategies that combine ABBV-CLS-484 with VEGF TKIs, CAR-T therapy, and T cell engagers are being tested in preclinical models.

H. Hammers, E. Calvo, B. Carneiro et al. · 0 citations
Clinical trial Open access Sep 2026

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors

Abstract Background SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, effi...

E. Dumbrava, Do-Youn Oh, Min-Hee Ryu et al. · 0 citations
Open access Aug 2026

Prognostic stratification by LGR5 expression identifies surface-accessible, structurally ligandable and condensate-forming targets in colorectal cancer

LGR5 expression defines a colorectal cancer subset that is pharmacologically tractable despite the absence of genetic dependency, including condensate-directed modulation of NKD1 as a route to targets inaccessible by antibody- or pocket-based approaches.

Lucía Paniagua-Herranz, A. Feito, Cristian Privat et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.